1216 related articles for article (PubMed ID: 26560336)
1. Discriminative Power of Arterial Spin Labeling Magnetic Resonance Imaging and 18F-Fluorodeoxyglucose Positron Emission Tomography Changes for Amyloid-β-Positive Subjects in the Alzheimer's Disease Continuum.
Tosun D; Schuff N; Jagust W; Weiner MW;
Neurodegener Dis; 2016; 16(1-2):87-94. PubMed ID: 26560336
[TBL] [Abstract][Full Text] [Related]
2. Decoupling of Regional Cerebral Blood Flow and Brain Function Along the Alzheimer's Disease Continuum.
Li J; Zeng Q; Luo X; Li K; Liu X; Hong L; Zhang X; Zhong S; Qiu T; Liu Z; Chen Y; Huang P; Zhang M;
J Alzheimers Dis; 2023; 95(1):287-298. PubMed ID: 37483006
[TBL] [Abstract][Full Text] [Related]
3. Hybrid PET/MRI with Flutemetamol and FDG in Alzheimer's Disease Clinical Continuum.
Atay LO; Saka E; Akdemir UO; Yetim E; Balcı E; Arsava EM; Topcuoglu MA
Curr Alzheimer Res; 2023; 20(7):481-495. PubMed ID: 38050727
[TBL] [Abstract][Full Text] [Related]
4. Pattern of cerebral hypoperfusion in Alzheimer disease and mild cognitive impairment measured with arterial spin-labeling MR imaging: initial experience.
Johnson NA; Jahng GH; Weiner MW; Miller BL; Chui HC; Jagust WJ; Gorno-Tempini ML; Schuff N
Radiology; 2005 Mar; 234(3):851-9. PubMed ID: 15734937
[TBL] [Abstract][Full Text] [Related]
5. Selecting the most relevant brain regions to discriminate Alzheimer's disease patients from healthy controls using multiple kernel learning: A comparison across functional and structural imaging modalities and atlases.
Rondina JM; Ferreira LK; de Souza Duran FL; Kubo R; Ono CR; Leite CC; Smid J; Nitrini R; Buchpiguel CA; Busatto GF
Neuroimage Clin; 2018; 17():628-641. PubMed ID: 29234599
[TBL] [Abstract][Full Text] [Related]
6. Cognitive dispersion is elevated in amyloid-positive older adults and associated with regional hypoperfusion.
Holmqvist SL; Thomas KR; Edmonds EC; Calcetas A; Edwards L; Bangen KJ;
J Int Neuropsychol Soc; 2023 Aug; 29(7):621-631. PubMed ID: 36093903
[TBL] [Abstract][Full Text] [Related]
7. Longer-Term Investigation of the Value of 18F-FDG-PET and Magnetic Resonance Imaging for Predicting the Conversion of Mild Cognitive Impairment to Alzheimer's Disease: A Multicenter Study.
Inui Y; Ito K; Kato T;
J Alzheimers Dis; 2017; 60(3):877-887. PubMed ID: 28922157
[TBL] [Abstract][Full Text] [Related]
8. Plasma Aβ42/40 ratio alone or combined with FDG-PET can accurately predict amyloid-PET positivity: a cross-sectional analysis from the AB255 Study.
Pérez-Grijalba V; Arbizu J; Romero J; Prieto E; Pesini P; Sarasa L; Guillen F; Monleón I; San-José I; Martínez-Lage P; Munuera J; Hernández I; Buendía M; Sotolongo-Grau O; Alegret M; Ruiz A; Tárraga L; Boada M; Sarasa M;
Alzheimers Res Ther; 2019 Dec; 11(1):96. PubMed ID: 31787105
[TBL] [Abstract][Full Text] [Related]
9. Biomarker-Based Prediction of Longitudinal Tau Positron Emission Tomography in Alzheimer Disease.
Leuzy A; Smith R; Cullen NC; Strandberg O; Vogel JW; Binette AP; Borroni E; Janelidze S; Ohlsson T; Jögi J; Ossenkoppele R; Palmqvist S; Mattsson-Carlgren N; Klein G; Stomrud E; Hansson O
JAMA Neurol; 2022 Feb; 79(2):149-158. PubMed ID: 34928318
[TBL] [Abstract][Full Text] [Related]
10. Cerebral perfusion and glucose metabolism in Alzheimer's disease and frontotemporal dementia: two sides of the same coin?
Verfaillie SC; Adriaanse SM; Binnewijzend MA; Benedictus MR; Ossenkoppele R; Wattjes MP; Pijnenburg YA; van der Flier WM; Lammertsma AA; Kuijer JP; Boellaard R; Scheltens P; van Berckel BN; Barkhof F
Eur Radiol; 2015 Oct; 25(10):3050-9. PubMed ID: 25899416
[TBL] [Abstract][Full Text] [Related]
11. Comparison of the diagnostic performance of FDG-PET and VBM-MRI in very mild Alzheimer's disease.
Kawachi T; Ishii K; Sakamoto S; Sasaki M; Mori T; Yamashita F; Matsuda H; Mori E
Eur J Nucl Med Mol Imaging; 2006 Jul; 33(7):801-9. PubMed ID: 16550383
[TBL] [Abstract][Full Text] [Related]
12. White matter lesion load is associated with resting state functional MRI activity and amyloid PET but not FDG in mild cognitive impairment and early Alzheimer's disease patients.
Zhou Y; Yu F; Duong TQ;
J Magn Reson Imaging; 2015 Jan; 41(1):102-9. PubMed ID: 24382798
[TBL] [Abstract][Full Text] [Related]
13. Regional fluorodeoxyglucose metabolism and instrumental activities of daily living across the Alzheimer's disease spectrum.
Roy K; Pepin LC; Philiossaint M; Lorius N; Becker JA; Locascio JJ; Rentz DM; Sperling RA; Johnson KA; Marshall GA
J Alzheimers Dis; 2014; 42(1):291-300. PubMed ID: 24898635
[TBL] [Abstract][Full Text] [Related]
14. Categorical and correlational analyses of baseline fluorodeoxyglucose positron emission tomography images from the Alzheimer's Disease Neuroimaging Initiative (ADNI).
Langbaum JB; Chen K; Lee W; Reschke C; Bandy D; Fleisher AS; Alexander GE; Foster NL; Weiner MW; Koeppe RA; Jagust WJ; Reiman EM;
Neuroimage; 2009 May; 45(4):1107-16. PubMed ID: 19349228
[TBL] [Abstract][Full Text] [Related]
15. Glucose metabolism during resting state reveals abnormal brain networks organization in the Alzheimer's disease and mild cognitive impairment.
Sanabria-Diaz G; Martínez-Montes E; Melie-Garcia L;
PLoS One; 2013; 8(7):e68860. PubMed ID: 23894356
[TBL] [Abstract][Full Text] [Related]
16. Exploring brain glucose metabolic patterns in cognitively normal adults at risk of Alzheimer's disease: A cross-validation study with Chinese and ADNI cohorts.
Li TR; Dong QY; Jiang XY; Kang GX; Li X; Xie YY; Jiang JH; Han Y;
Neuroimage Clin; 2022; 33():102900. PubMed ID: 34864286
[TBL] [Abstract][Full Text] [Related]
17. Voxel-based analysis of Alzheimer's disease PET imaging using a triplet of radiotracers: PIB, FDDNP, and FDG.
Shin J; Lee SY; Kim SJ; Kim SH; Cho SJ; Kim YB
Neuroimage; 2010 Aug; 52(2):488-96. PubMed ID: 20385246
[TBL] [Abstract][Full Text] [Related]
18. PET of brain amyloid and tau in mild cognitive impairment.
Small GW; Kepe V; Ercoli LM; Siddarth P; Bookheimer SY; Miller KJ; Lavretsky H; Burggren AC; Cole GM; Vinters HV; Thompson PM; Huang SC; Satyamurthy N; Phelps ME; Barrio JR
N Engl J Med; 2006 Dec; 355(25):2652-63. PubMed ID: 17182990
[TBL] [Abstract][Full Text] [Related]
19. Two-year follow-up of amyloid deposition in patients with Alzheimer's disease.
Engler H; Forsberg A; Almkvist O; Blomquist G; Larsson E; Savitcheva I; Wall A; Ringheim A; Långström B; Nordberg A
Brain; 2006 Nov; 129(Pt 11):2856-66. PubMed ID: 16854944
[TBL] [Abstract][Full Text] [Related]
20. Patterns of Distribution of 18F-THK5351 Positron Emission Tomography in Alzheimer's Disease Continuum.
Nihashi T; Sakurai K; Kato T; Iwata K; Kimura Y; Ikenuma H; Yamaoka A; Takeda A; Arahata Y; Washimi Y; Suzuki K; Bundo M; Sakurai T; Okamura N; Yanai K; Ito K; Nakamura A;
J Alzheimers Dis; 2022; 85(1):223-234. PubMed ID: 34776443
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
